Interleukin-2 and leukemia

Mark Goodman, L. Cabral, P. Cassileth

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Leukemia has been treated with chemotherapy for the past 40 years with only moderate success. A growing body of evidence suggests that by augmenting the immune system more effective results may be obtained. This is highlighted by T cell reinfusions resulting in durable remissions in patients with chronic myelogenous leukemia who have relapsed after an allogeneic transplant. Interleukin-2 is the primary growth factor for T lymphocytes and is a stimulator of natural killer cell activity. It has now been shown that a limited number of otherwise refractory leukemias can be effectively treated with interleukin-2. However, there remains a lack of correlation between the biologic and clinical effects of interleukin-2. The clinical activity of interleukin-2 appears to be greatest in myeloid leukemias. A variety of dose schedules and routes of administration make it difficult to determine if interleukin-2 given to patients in clinical remission is of benefit. Large randomized studies are necessary to explore the role of interleukin-2 in leukemia.

Original languageEnglish
Pages (from-to)1671-1675
Number of pages5
JournalLeukemia
Volume12
Issue number11
StatePublished - Nov 16 1998

Fingerprint

Interleukin-2
Leukemia
T-Lymphocytes
Myeloid Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Natural Killer Cells
Immune System
Intercellular Signaling Peptides and Proteins
Appointments and Schedules
Transplants
Drug Therapy

Keywords

  • Bone marrow transplant
  • Interleukin-2
  • Leukemia
  • T cells

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Goodman, M., Cabral, L., & Cassileth, P. (1998). Interleukin-2 and leukemia. Leukemia, 12(11), 1671-1675.

Interleukin-2 and leukemia. / Goodman, Mark; Cabral, L.; Cassileth, P.

In: Leukemia, Vol. 12, No. 11, 16.11.1998, p. 1671-1675.

Research output: Contribution to journalArticle

Goodman, M, Cabral, L & Cassileth, P 1998, 'Interleukin-2 and leukemia', Leukemia, vol. 12, no. 11, pp. 1671-1675.
Goodman M, Cabral L, Cassileth P. Interleukin-2 and leukemia. Leukemia. 1998 Nov 16;12(11):1671-1675.
Goodman, Mark ; Cabral, L. ; Cassileth, P. / Interleukin-2 and leukemia. In: Leukemia. 1998 ; Vol. 12, No. 11. pp. 1671-1675.
@article{9374d10de63b4fd281914cb897048fb9,
title = "Interleukin-2 and leukemia",
abstract = "Leukemia has been treated with chemotherapy for the past 40 years with only moderate success. A growing body of evidence suggests that by augmenting the immune system more effective results may be obtained. This is highlighted by T cell reinfusions resulting in durable remissions in patients with chronic myelogenous leukemia who have relapsed after an allogeneic transplant. Interleukin-2 is the primary growth factor for T lymphocytes and is a stimulator of natural killer cell activity. It has now been shown that a limited number of otherwise refractory leukemias can be effectively treated with interleukin-2. However, there remains a lack of correlation between the biologic and clinical effects of interleukin-2. The clinical activity of interleukin-2 appears to be greatest in myeloid leukemias. A variety of dose schedules and routes of administration make it difficult to determine if interleukin-2 given to patients in clinical remission is of benefit. Large randomized studies are necessary to explore the role of interleukin-2 in leukemia.",
keywords = "Bone marrow transplant, Interleukin-2, Leukemia, T cells",
author = "Mark Goodman and L. Cabral and P. Cassileth",
year = "1998",
month = "11",
day = "16",
language = "English",
volume = "12",
pages = "1671--1675",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Interleukin-2 and leukemia

AU - Goodman, Mark

AU - Cabral, L.

AU - Cassileth, P.

PY - 1998/11/16

Y1 - 1998/11/16

N2 - Leukemia has been treated with chemotherapy for the past 40 years with only moderate success. A growing body of evidence suggests that by augmenting the immune system more effective results may be obtained. This is highlighted by T cell reinfusions resulting in durable remissions in patients with chronic myelogenous leukemia who have relapsed after an allogeneic transplant. Interleukin-2 is the primary growth factor for T lymphocytes and is a stimulator of natural killer cell activity. It has now been shown that a limited number of otherwise refractory leukemias can be effectively treated with interleukin-2. However, there remains a lack of correlation between the biologic and clinical effects of interleukin-2. The clinical activity of interleukin-2 appears to be greatest in myeloid leukemias. A variety of dose schedules and routes of administration make it difficult to determine if interleukin-2 given to patients in clinical remission is of benefit. Large randomized studies are necessary to explore the role of interleukin-2 in leukemia.

AB - Leukemia has been treated with chemotherapy for the past 40 years with only moderate success. A growing body of evidence suggests that by augmenting the immune system more effective results may be obtained. This is highlighted by T cell reinfusions resulting in durable remissions in patients with chronic myelogenous leukemia who have relapsed after an allogeneic transplant. Interleukin-2 is the primary growth factor for T lymphocytes and is a stimulator of natural killer cell activity. It has now been shown that a limited number of otherwise refractory leukemias can be effectively treated with interleukin-2. However, there remains a lack of correlation between the biologic and clinical effects of interleukin-2. The clinical activity of interleukin-2 appears to be greatest in myeloid leukemias. A variety of dose schedules and routes of administration make it difficult to determine if interleukin-2 given to patients in clinical remission is of benefit. Large randomized studies are necessary to explore the role of interleukin-2 in leukemia.

KW - Bone marrow transplant

KW - Interleukin-2

KW - Leukemia

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=0031786422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031786422&partnerID=8YFLogxK

M3 - Article

C2 - 9823939

AN - SCOPUS:0031786422

VL - 12

SP - 1671

EP - 1675

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -